Zinlirvimab: Clinical Trials

2 recruiting, 1 active not recruiting, 1 completed, 1 suspended. 2 Phase 1, 2 Phase 2, 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 1	2	Completed 1, Suspended 1
Phase 2	2	Active not recruiting 1, Suspended 1
Phase 3	2	Recruiting 2

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV Infections	Phase 3	Recruiting	Gilead Sciences	590	2026-07-14	2026-08-14
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens Lenacapavir, Lenacapavir Tablet, Teropavimab - HIV-1-infection	Phase 3	Recruiting	Gilead Sciences	590	2026-07-14	2026-07-30
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1 ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3 - HIV-1-infection	Phase 1 / Phase 2	Suspended	National Institute of Allergy and Infectious Diseases (NIAID)	36	2024-04-01	2026-09-02
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Teropavimab, Zinlirvimab, Lenacapavir Tablet - HIV-1 Infection	Phase 2	Active not recruiting	Gilead Sciences	83	2023-05-15	2026-04-27
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection Oral Lenacapavir, Subcutaneous Lenacapavir, Teropavimab - HIV-1 Infection	Phase 1	Completed	Gilead Sciences	32	2021-04-08	2025-01-27

United States (5) · Australia (2) · Brazil (1) · Canada (1) · Japan (1) · Puerto Rico (1)

2025 (2)